体内生成的抗FAP CAR T细胞减少代谢功能障碍相关脂肪性肝炎的纤维化并恢复肝脏稳态
研究在代谢功能障碍相关脂肪性肝炎(MASH)小鼠模型中,证实FAP在人和小鼠MASH中特异性表达于肝星状细胞(HSC);携带抗FAP CAR信使RNA的抗CD5靶向脂质纳米颗粒可在体内瞬时生成激活的抗FAP CAR T细胞,通过清除促纤维化HSC显著减少纤维化,并以非细胞自主方式调节免疫细胞、内皮细胞和肝细胞以减轻炎症、恢复肝脏稳态。
要点
- FAP在人和小鼠MASH中特异性表达于肝星状细胞。
- 体内生成的抗FAP CAR T细胞通过清除促纤维化HSC显著减少小鼠MASH纤维化。
- 该疗法还以非细胞自主方式调节免疫细胞、内皮细胞和肝细胞,减轻炎症并恢复肝脏稳态。
核心结论
- 体内生成的抗FAP CAR T细胞疗法不仅通过直接减少纤维化,还通过对其他细胞类型的间接作用,有望减轻MASH这一高发病率肝病。
研究设计与样本
- 研究为动物实验,采用小鼠MASH模型评估体内生成的抗FAP CAR T细胞疗法的抗纤维化作用。
- 使用携带抗FAP CAR信使RNA的抗CD5靶向脂质纳米颗粒在体内瞬时生成激活的抗FAP CAR T细胞。
- 采用流式细胞术、天狼星红形态计量学、数字病理分析和单核RNA测序评估治疗对小鼠MASH的影响。
主要发现
- FAP在人和小鼠MASH中特异性表达于肝星状细胞。
- 抗FAP CAR T细胞显著减少小鼠MASH纤维化,机制为清除促纤维化肝星状细胞。
- 抗FAP CAR T细胞以非细胞自主方式调节免疫细胞、内皮细胞和肝细胞,减轻炎症并恢复肝脏稳态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatic fibrosis is a key predictor of mortality in liver disease, driven by fibrogenic hepatic stellate cells (HSCs). Targeting these fibrogenic cells may therefore offer a therapeutic approach for hepatic fibrosis. We previously showed that in vivo-generated chimeric antigen receptor (CAR) T cells targeting fibroblast activation protein alpha (FAP) reduced murine cardiac fibrosis. Here, we explored the antifibrotic potential of this in vivo-generated anti-FAP CAR T cell therapy in metabolic dysfunction-associated steatohepatitis (MASH), a highly prevalent disease with no approved antifibrotic therapies. We first established that FAP expression in both human and murine MASH is specific to HSCs. We then used flow cytometry, Sirius Red morphometry, digital pathology analysis, and single nuclear RNA sequencing to assess the impact of anti-FAP CAR T cell therapy on murine MASH. Anti-CD5-targeted lipid nanoparticles carrying anti-FAPCAR messenger RNA transiently generated activated anti-FAP CAR T cells, which substantially reduced fibrosis by depleting profibrogenic HSCs. They also modulated immune cells, endothelial cells, and hepatocytes in a non-cell autonomous manner to mitigate inflammation and restore hepatic homeostasis. These findings highlight the potential of in vivo CAR T therapy to attenuate a highly morbid and pervasive liver disease, not only by directly reducing fibrosis but also through indirect effects on other cell types.
引用
- Yashaswini CN, Cogliati B, Qin T, et al. Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis. Sci Transl Med. 2026. PMID: 41564158. doi:10.1126/scitranslmed.adx0368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。